Investigation of amino acid conjugates of (S)-1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282) as water soluble anticancer prodrugs

• Arylsulfonylimidazolidinone (DW2282) was reported as anti-cancer agent.
• The amino acid conjugates of arylsulfonylimidazolidinone were prepared.
• DW2282-l-Phe (1e) and DW2282-l-Leu (1g) have good reconversion profile.
• 1e and 1g show good pharmacokinetic profile and in vivo anti-cancer activity.
• 1e and 1g are considered as prodrugs.

The amino acid-conjugates (1a–k) with eleven amino acids attached to primary amine of (S)-1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one (DW2282, 1) were prepared and studied for their prodrug characteristics and anti-cancer activity against SW620 cell line. All the amino acid derivatives showed not only improved water solubility but also displayed potent anti-cancer activity in vitro. Among these amino acid-conjugates the compounds, DW2282-l-Ala (1b), DW2282-l-Phe (1e), DW2282-l-Leu (1g) and DW2282-l-Met (1h) showed good reconversion within 8 h (104.76%, 84.03%, 95.02% and 78.34%, respectively) to the parent drug in human plasma. In addition, the compounds 1e, 1g and 1j also showed good bioavailability profile along with potent in vivo anticancer activity.

Figure optionsDownload as PowerPoint slide